Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Phase 1
Withdrawn
- Conditions
- Recurrent Pancreatic CancerStage IV Pancreatic CancerDuct Cell Adenocarcinoma of the PancreasStage III Pancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT02048943
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Icotinib Hydrochloride in Treating Patients With Advanced Cancers
Phase 1
Withdrawn
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2014-11-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT02033148
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2
Terminated
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeUntreated Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT02029417
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Phase 1
Withdrawn
- Conditions
- Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IA Fallopian Tube CancerStage IA Ovarian Epithelial CancerStage IA Primary Peritoneal Cavity CancerStage IB Fallopian Tube CancerStage IB Ovarian Epithelial CancerStage IB Primary Peritoneal Cavity CancerStage IC Fallopian Tube Cancer
- Interventions
- Drug: IDO1 inhibitor INCB024360Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccineOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT01982487
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase 1
Withdrawn
- Conditions
- Recurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung CancerAdult Solid Neoplasm
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Questionnaire Administration
- First Posted Date
- 2013-10-29
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT01971489
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Phase 1
Active, not recruiting
- Conditions
- Stage I Diffuse Large B-Cell LymphomaStage III Diffuse Large B-Cell LymphomaCD20 PositiveStage IV Diffuse Large B-Cell LymphomaStage II Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyBiological: Rituximab
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT01959698
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Phase 2
Completed
- Conditions
- Recurrent Non-small Cell Lung CancerStage III Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerSquamous Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT01948141
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈUniversity Hospitals Case Medical Center, Cleveland, Ohio, United States
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
Not Applicable
Completed
- Conditions
- Soft Tissue SarcomaMalignant NeoplasmOvarian NeoplasmBreast CarcinomaColon CarcinomaKidney NeoplasmLung CarcinomaMelanomaAdult Liver CarcinomaMalignant Head and Neck Neoplasm
- Interventions
- Procedure: Hyperthermia TreatmentOther: Laboratory Biomarker Analysis
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT01896778
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
Not Applicable
Completed
- Conditions
- Stage IV Renal Cell CancerRecurrent Renal Cell Cancer
- Interventions
- Radiation: stereotactic body radiation therapyProcedure: therapeutic conventional surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT01892930
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
Not Applicable
Completed
- Conditions
- Recurrent MelanomaStage IA Skin MelanomaStage IB Skin MelanomaStage IIA Skin MelanomaStage IIB Skin MelanomaStage IIC Skin MelanomaStage IIIB Skin MelanomaStage IV Skin MelanomaStage IIIA Skin MelanomaStage IIIC Skin Melanoma
- Interventions
- Procedure: Diagnostic MicroscopyOther: Laboratory Biomarker AnalysisProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01886235
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States